Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBV712 epicutaneous immunotherapy in peanut-allergic children aged 4-7
NCT05741476Phase 3Active, not recruiting
- Sponsor
- DBV Technologies
- Start
- Feb 2023
- Primary completion
- Nov 2025
- Modality
- Transdermal Patches
- Countries
- 9
01
Overview
A Phase 3 trial of DBV712 Viaskin® in peanut allergy, sponsored by DBV Technologies. Started Feb 2023; status: active, not recruiting.
02
Drugs
DBV712 Viaskin®
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT05741476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741476.